Drug Profile
Aflibercept biosimilar - Alteogen
Alternative Names: ALT L9; Eylea® Biosimilar - AlteogenLatest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Alteogen
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Wet age-related macular degeneration
Most Recent Events
- 22 Feb 2023 Alteogen expects the approval of aflibercept biosimilar for Wet age-related macular degeneration from the regulatory authorities by first half of 2025
- 22 Feb 2023 Alteogen plans to submit the Biologics License Application (BLA) for Wet age-related macular degeneration in early 2024
- 22 Feb 2023 Alteogen completes enrolment in the phase III trial in Wet age-related macular degeneration (Newly diagnosed, Treatment-naive) in Hungary (Intravitreous) (EudraCT2021-004530-11)